One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis (MS) drug Ocrevus ahead of an FDA decision, the Swiss pharma said. A subcutaneous ...
Injectable medications for multiple sclerosis (MS) are disease-modifying therapies (DMTs) that work by slowing or changing the progression of the condition. Options include interferons, glatiramer ...
Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...
As of 2022, there were 15 oral and injectable MS drugs across seven types of "classes," or groups of medication that work in similar ways. These treatments are all pricey, usually costing $5,000 to ...
* Peg-Avonex shown safe and effective * Drug designed to reduce interferon dosing schedules * Analysts have modest expectations for product (Updates with additional analyst comment, share price) Jan ...
– Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office – – This approval is backed by a decade of proven ...
Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...
The FDA warns that the injectable MS drugs Copaxone and Glatopa (glatiramer acetate) can cause rare, potentially fatal allergic reactions. These drugs can result in anaphylactic shock, which can slow ...
As of 2022, there were 15 oral and injectable MS drugs across seven types of "classes," or groups of medication that work in similar ways. These treatments are all pricey, usually costing $5,000 to ...
As of 2022, there were 15 oral and injectable MS drugs across seven types of "classes," or groups of medication that work in similar ways. These treatments are all pricey, usually costing $5,000 to ...
Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results